Iamna (Ethinylestradiol, Gestodene | Lactose Monohydrate)

The two hormones act on the hypothalamic‑pituitary‑ovarian axis. Ethynylestradiol suppresses the surge of follicle‑stimulating hormone, while gestodene blocks luteinising hormone release. This dual suppression stops follicle maturation and ovulation. Additionally, gestodene thickens cervical mucus and alters the endometrium, preventing fertilisation and implantation.

The dosing regimen for Iamna is determined by the prescribing clinician. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule, including any missed‑dose instructions, must be confirmed by a qualified healthcare professional.

Iamna is contraindicated in pregnancy and should not be started or continued by women who are pregnant. While limited data exist for breastfeeding, most guidelines advise caution; the benefits and risks should be evaluated by a healthcare provider before use during lactation.

To request Iamna, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Iamna contains ethynylestradiol and gestodene, a second‑generation progestogen known for a favorable bleeding profile and lower androgenic activity compared with some older formulations. Its efficacy in preventing pregnancy is comparable to other combined pills, while the side‑effect spectrum may differ slightly based on the progestogen component.

Iamna tablets should be stored at ambient temperature below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Iamna is taken orally as a single tablet each day, preferably at the same time each day. The tablet is swallowed whole with water and should be started on the first day of the menstrual cycle or as directed by a healthcare professional.

The most serious risks include venous thromboembolism, arterial thrombosis (such as stroke or myocardial infarction), severe hypertension, and rare hepatic tumors. Women with a history of clotting disorders, smoking over age 35, or uncontrolled hypertension should be closely monitored or avoid use.

Iamna is contraindicated for women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic events, uncontrolled hypertension, severe liver disease, or are smokers aged 35 years or older. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.